Alterity Therapeutics LtdNASDAQ:ATHE
- LAST PRICE2.1314
- TODAY'S CHANGE (%)0.0014 (0.0657%)
- Bid / Lots2.1300/ 2
- Ask / Lots2.1500/ 2
- Open / Previous Close2.1000 / 2.1300
- Day Range
- 52 Week Range
- Volume30,819
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATHE |
|---|---|---|
| 09:32 ET | 294 | 2.1 |
| 09:52 ET | 479 | 2.035 |
| 10:01 ET | 1201 | 2.11 |
| 10:03 ET | 1500 | 2.14 |
| 10:06 ET | 200 | 2.1847 |
| 10:33 ET | 100 | 2.1787 |
| 10:51 ET | 100 | 2.1719 |
| 10:53 ET | 100 | 2.154 |
| 10:55 ET | 534 | 2.17 |
| 11:06 ET | 920 | 2.16 |
| 11:31 ET | 100 | 2.1207 |
| 11:44 ET | 100 | 2.15 |
| 11:47 ET | 500 | 2.15 |
| 11:51 ET | 200 | 2.13 |
| 11:58 ET | 100 | 2.145 |
| 12:32 ET | 200 | 2.1599 |
| 12:50 ET | 2600 | 2.1262 |
| 12:56 ET | 1000 | 2.14 |
| 01:08 ET | 4980 | 2.15 |
| 01:12 ET | 200 | 2.15 |
| 01:17 ET | 100 | 2.135 |
| 01:55 ET | 419 | 2.14 |
| 01:57 ET | 500 | 2.1592 |
| 02:00 ET | 200 | 2.15 |
| 02:04 ET | 125 | 2.15 |
| 02:08 ET | 100 | 2.14 |
| 02:26 ET | 100 | 2.15 |
| 02:29 ET | 100 | 2.15 |
| 02:33 ET | 100 | 2.1599 |
| 02:40 ET | 588 | 2.16 |
| 02:42 ET | 219 | 2.16 |
| 02:51 ET | 100 | 2.15 |
| 02:58 ET | 975 | 2.16 |
| 03:03 ET | 462 | 2.14 |
| 03:16 ET | 100 | 2.15 |
| 03:30 ET | 200 | 2.15 |
| 03:34 ET | 1243 | 2.15 |
| 03:45 ET | 3089 | 2.15 |
| 03:48 ET | 141 | 2.1699 |
| 03:50 ET | 350 | 2.17 |
| 03:52 ET | 843 | 2.1314 |
Apr 17, 2024
Apr 10, 2024
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024, from 7:25AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:25AM ET on Wednesday Apr 10, 2024 by Dow Jones
Mar 26, 2024
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund, from 10:25AM ET on Tuesday Mar 26, 2024 by Dow Jones
10:25AM ET on Tuesday Mar 26, 2024 by Dow JonesPress Release: Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund, from 10:25AM ET on Tuesday Mar 26, 2024 by Dow Jones
10:25AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alterity Therapeutics Ltd | 18.5M | -1.1x | --- |
Imunon Inc | 11.9M | -0.6x | --- |
Inhibitor Therapeutics Inc | 11.8M | -3.2x | --- |
Eterna Therapeutics Inc | 11.6M | -0.5x | --- |
Mira Pharmaceuticals Inc | 12.6M | -1.0x | --- |
Monopar Therapeutics Inc | 11.0M | -1.1x | --- |
Company Information
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Contact Information
- Headquarters
- L 3 460 Bourke StMELBOURNE, VIC, Australia 3000
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Geoffrey Kempler
- Chief Executive Officer
- David Stamler
- Chief Financial Officer, Company Secretary
- Phillip Hains
- Non-Executive Director
- Lawrence Gozlan
- Non-Executive Independent Director
- Peter Marks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.5M |
|---|---|
Revenue (TTM) | $79.6K |
Shares Outstanding | 8.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.92 |
EPS | $-1.92 |
Book Value | $3.62 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 232.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -11,563.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
